Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2022 07:30 ET | Source: SIGA Technologies Inc.

SIGA Declares Special Dividend of $0.45 Per Share

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special...
April 28, 2022 16:05 ET | Source: SIGA Technologies Inc.

SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
March 03, 2022 16:05 ET | Source: SIGA Technologies Inc.

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021

- Approximately $113 Million of U.S. Product Sales in 2021 – - Approximately $13 Million of International Product Sales in 2021 – - Corporate Update Conference Call Today at 4:30...
March 02, 2022 07:30 ET | Source: SIGA Technologies Inc.

SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
February 24, 2022 10:27 ET | Source: SIGA Technologies Inc.

SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
January 25, 2022 07:30 ET | Source: SIGA Technologies Inc.

SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech

NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
January 18, 2022 07:30 ET | Source: SIGA Technologies Inc.

SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it...
January 10, 2022 07:30 ET | Source: SIGA Technologies Inc.

SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
December 01, 2021 09:55 ET | Source: SIGA Technologies Inc.

SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that...
November 16, 2021 08:30 ET | Source: SIGA Technologies Inc.

European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat

- Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications - NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a...